Stay updated with breaking news from Alan Sandler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.
SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that following a re-examination...
Mirati Therapeutics has received conditional marketing authorisation approval from the MHRA for its NSCLC therapy, Krazati.
SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare...
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and...